Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 101 publications
Sodium-Glucose Cotransporter 2 Inhibitors and Dementia Risk in Patients With Psychiatric Disorders.
Journal: JAMA network open
Published: June 30, 2026
High prevalence of CNS-directed autoantibodies in patients with schizophrenia.
Journal: bioRxiv : the preprint server for biology
Published: May 18, 2026
With No Surprises From the EMERGENT-4 Trial, Where Do We Go From Here?
Journal: The American journal of psychiatry
Published: March 01, 2026
Modern Causal Inference Approaches to Improve Power for Subgroup Analysis in Randomized Controlled Trials.
Journal: Statistics in medicine
Published: July 07, 2025
Reply to "Xanomeline/Trospium Combination: Not Non-dopaminergic but a Novel Antidopaminergic Treatment for Schizophrenia".
Journal: Journal of clinical psychopharmacology
Published: March 07, 2025
Impaired Hippocampal Circuitry and Memory Dysfunction in Schizophrenia.
Journal: Nature. Mental health
Published: March 01, 2025
Hippocampal perfusion abnormalities and treatment effects in acute phase of first-episode schizophrenia.
Journal: Schizophrenia research
Published: February 10, 2025
At Last, a Nondopaminergic Agent for the Treatment of Schizophrenia: The Combination of Xanomeline and Trospium (Cobenfy).
Journal: Journal of clinical psychopharmacology
Published: February 06, 2025
Why Do Veterans Not Respond as Well as Civilians to Trauma-Focused Therapies for PTSD?
Journal: Harvard review of psychiatry
Published: July 11, 2024
Anti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder.
Journal: Brain, behavior, & immunity - health
Published: May 29, 2024
Another Step Toward the Prediction of Antipsychotic Treatment Response Using Functional Connectivity.
Journal: The American journal of psychiatry
Published: November 01, 2023
Last Updated: 09/26/2026